背景:由鲍曼不动杆菌引起的感染是医院环境中健康问题的主要原因。此外,鲍曼不动杆菌的极端耐药性的存在使得治疗方案变得更具挑战性,因为治疗方案有限,因此鼓励研究人员探索现有的抗菌药物来对抗由它们引起的感染.这项研究的重点是多药耐药鲍曼不动杆菌(MDR-AB)菌株对米诺环素和粘菌素的敏感性。
方法:从2022年6月至2023年6月进行了横断面研究。从各种临床样本中获得的100株鲍曼不动杆菌被送往中央实验室,微生物学系,SreeBalaji医学院和医院,Chrompet,钦奈,印度。根据临床和实验室标准协会(CLSI)指南进行抗菌药物敏感性测试,2022年。对于标准抗生素,进行了圆盘扩散法。对于米诺环素和粘菌素,最小抑制浓度(MIC)采用ε-silometer试纸条(E-strip)测定.
结果:在这项研究中,获得了100株鲍曼不动杆菌,83%的分离株具有多重耐药性。在MDR-AB中,50(60%)对米诺环素敏感,40(48%)对粘菌素敏感。在40株对粘菌素敏感的鲍曼不动杆菌菌株中,29例(73%)对米诺环素易感,P值<0.05具有统计学意义。在43株粘菌素抗性鲍曼不动杆菌中,21例(53%)对米诺环素易感,P值<0.05具有统计学意义。
结论:当考虑到治疗产生碳青霉烯酶的革兰氏阴性菌的费用时,粘菌素和二甲胺四环素可以用作替代药物,因为它们副作用更少,更实惠。米诺环素可以用作粘菌素的替代品,因为它可以从可注射制剂转化为口服制剂。
BACKGROUND: Infections caused by Acinetobacter baumannii are a major cause of health concerns in the hospital setting. Moreover, the presence of extreme drug resistance in A. baumannii has made the scenario more challenging due to limited treatment options thereby encouraging the researchers to explore the existing antimicrobial agents to combat the infections caused by them. This study focuses on the susceptibility of multi-drug-resistant A. baumannii (MDR-AB) strains to
minocycline and also to colistin.
METHODS: A cross-sectional study was conducted from June 2022 to June 2023. One hundred isolates of A. baumannii obtained from various clinical samples were sent to Central Laboratory, Department of Microbiology, Sree Balaji Medical College and Hospital, Chrompet, Chennai, India. The antimicrobial susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines, 2022. For the standard antibiotics, the disc diffusion method was performed. For
minocycline and colistin, the minimum inhibitory concentration (MIC) was determined using an epsilometer strip (E-strip) test.
RESULTS: In this study, 100 isolates of A. baumannii were obtained, and 83% of the isolates were multi-drug-resistant. Among the MDR-AB, 50 (60%) were susceptible to
minocycline and 40 (48%) were susceptible to colistin. Out of the 40 colistin-susceptible A. baumannii strains, 29 (73%) were susceptible to
minocycline with a statistically significant P-value of <0.05. Among the 43 colistin-resistant A. baumannii strains, 21 (53%) were susceptible to
minocycline with a statistically significant P-value of <0.05.
CONCLUSIONS: When taking into account the expense of treating carbapenemase-producing Gram-negative bacteria, colistin and minocycline can be used as an alternative drug as they have fewer side effects and are more affordable. Minocycline can be used as an alternative to colistin because it is feasible to convert from an injectable to an oral formulation.